Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director · President and CEO | August 15, 2022 | August 16, 2022 |
| Clovis Oncology, Inc.CLVS · Entity 122635 | Director | June 10, 2021 | June 11, 2021 |
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director · PRESIDENT AND CEO | December 11, 2025 | December 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BELLICUM PHARMACEUTICALS, INC
Report date August 15, 2022 · Filed August 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 · Expires 2032-08-15 | Direct | 400,000 |
Reported balance
After 2022-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-15 · Grant · Acquired 400,000 · Balance 400,000 F1: One-third (1/3rd) of the shares subject to the option will vest on the one-year anniversary on August 16, 2023, and the remaining shares will vest in twenty-four (24) equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3rd) of the shares subject to the option will vest on the one-year anniversary on August 16, 2023, and the remaining shares will vest in twenty-four (24) equal monthly installments thereafter.
Clovis Oncology, Inc.
Report date June 10, 2021 · Filed June 11, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.97 · Expires 2031-06-10 | Direct | 42,223 |
Reported balance
After 2021-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-10 · Grant · Acquired 42,223 · Balance 42,223 F1: The options shall vest on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options shall vest on the one-year anniversary of the date of grant.
Enliven Therapeutics, Inc.
Report date December 11, 2025 · Filed December 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.77 · Expires 2035-12-11 | Direct | 875,000 |
Reported balance
After 2025-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-11 · Grant · Acquired 875,000 · Balance 875,000 F1: 1/4th of the shares subject to the option will vest on December 11, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option will vest on December 11, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2025 Filed Dec 12, 2025 23:31 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 875,000 | $0.00 Strike: $18.77 | $0.00 |
DisclosureSEC source: 0001695851-25-000004 · form4-12122025_111226.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 875,000 Underlying: Common Stock · 875,000 shares Expires 2035-12-11 F1 · derivative.exercise_date: 1/4th of the shares subject to the option will vest on December 11, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 17:04 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 400,000 | $1.44 Strike: $1.44 | $576,000.00 |
DisclosureSEC source: 0001628280-22-023030 · wf-form4_166068384429200.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-08-15 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option will vest on the one-year anniversary on August 16, 2023, and the remaining shares will vest in twenty-four (24) equal monthly installments thereafter. Read SEC document |
| August 16, 2021 Filed Aug 16, 2021 16:21 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001628280-21-017115 · wf-form4_162914521751992.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2031-08-16 F1 · derivative.exercise_date: 50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter. Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 12:21 UTC Amendment | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 265,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001628280-21-017225 · wf-form4a_162930366124028.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,000 Underlying: Common Stock · 265,000 shares Expires 2031-08-16 F1 · derivative.exercise_price: This amendment is being filed to correct the typographical error in the exercise price of the stock option on the original Form 4 filed with the SEC on August 16, 2021 Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 20:48 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 42,223 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000899243-21-023392 · doc4.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,223 Underlying: Common Stock · 42,223 shares Expires 2031-06-10 F1 · derivative.exercise_date: The options shall vest on the one-year anniversary of the date of grant. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 13:54 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 286,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001628280-20-017550 · wf-form4_160814487996152.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,000 Underlying: Common Stock · 286,000 shares Expires 2030-12-14 F1 · derivative.exercise_date: 50% of the shares subject to the stock option vest and become exercisable on December 15, 2021, and the remaining shares subject to the stock option vest and become exercisable in 12 equal monthly installments thereafter. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:30 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 40,138 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0000899243-20-015705 · doc4.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,138 Underlying: Common Stock · 40,138 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option shall vest and become exercisable on the twelve (12) month anniversary of the date of grant. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 12:48 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | PurchaseCommon Stock | 5,000 | $4.00 | $19,998.50 |
DisclosureSEC source: 0001628280-20-003793 · wf-form4_158463650892986.xml · nonDerivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.97 to $4.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 14:24 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 1,257,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001628280-20-000991 · wf-form4_158084423487343.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,000 Underlying: Common Stock · 1,257,000 shares Expires 2030-02-02 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 3, 2021, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 19:01 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | PurchaseCommon Stock | 40,000 | $1.25 | $50,000.00 |
DisclosureSEC source: 0001209191-19-049227 · doc4.xml · nonDerivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,561 Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:03 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | PurchaseCommon Stock | 20,000 | $0.99 | $19,780.00 |
DisclosureSEC source: 0001358403-19-000111 · wf-form4_156659062257120.xml · nonDerivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,561 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9855 to $0.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2 · balance_after: Includes 6,561 shares acquired by the reporting person under the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 16:58 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001358403-19-000080 · wf-form4_156028666800640.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:45 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 28,882 | $0.00 Strike: $14.66 | $0.00 |
DisclosureSEC source: 0000899243-19-016034 · doc4.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,882 Underlying: Common Stock · 28,882 shares Expires 2029-06-06 F1 · derivative.exercise_date: One-twelfth (1/12) of the shares subject to the option shall vest on each of the first twelve (12) monthly anniversaries of the date of grant. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 16:10 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001358403-19-000021 · wf-form4_154940100228022.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 21:53 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 25,848 | $0.00 Strike: $27.92 | $0.00 |
DisclosureSEC source: 0000899243-18-026752 · doc4.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,848 Underlying: Common Stock · 25,848 shares Expires 2028-10-11 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option shall vest on each of the first three (3) annual anniversaries of the date of grant. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 16:02 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001358403-18-000073 · wf-form4_153082093661689.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-07-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:03 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantEmployee Stock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0001358403-18-000010 · wf-form4_151509977904246.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 2, 2019, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 16:11 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $11.87 | $0.00 |
DisclosureSEC source: 0001358403-17-000030 · wf-form4_148598349482649.xml · derivative · entry 1 Fair Richard A. · CIK 0001695851 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2027-01-29 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on January 30, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.